Misplaced Pages

Senaparib

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

Chemical compound

Pharmaceutical compound

Senaparib
Clinical data

Other names	IMP-4297
Legal status
Legal status	Invesigational
Identifiers
IUPAC name 5-fluoro-1-methyl]quinazoline-2,4-dione
CAS Number	1401682-78-7
PubChem CID	68389008
DrugBank	DB17163
ChemSpider	103704755
UNII	MNZ4OP95CF
ChEMBL	ChEMBL4802152
Chemical and physical data
Formula	C₂₄H₂₀F₂N₆O₃
Molar mass	478.460 g·mol
3D model (JSmol)	Interactive image
SMILES C1CN(CCN1C2=NC=CC=N2)C(=O)C3=C(C=CC(=C3)CN4C5=C(C(=CC=C5)F)C(=O)NC4=O)F
InChI InChI=1S/C24H20F2N6O3/c25-17-6-5-15(14-32-19-4-1-3-18(26)20(19)21(33)29-24(32)35)13-16(17)22(34)30-9-11-31(12-10-30)23-27-7-2-8-28-23/h1-8,13H,9-12,14H2,(H,29,33,35) Key:VBTUJTGLLREMNW-UHFFFAOYSA-N

Senaparib is an investigational new drug that is being evaluated to treat ovarian cancer. It is a PARP inhibitor.

References

"Senaparib - IMPACT Therapeutics". AdisInsight. Springer Nature Switzerland AG.
Cai SX, Ma N, Wang X, Guo M, Jiang Y, Tian YE (June 2024). "The discovery of a potent PARP1 inhibitor Senaparib". Molecular Cancer Therapeutics: OF1–OF9. doi:10.1158/1535-7163.MCT-23-0625. PMID 38920409.

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

v
t
e